Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
基本信息
- 批准号:10641775
- 负责人:
- 金额:$ 51.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-03-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAffectAllergic DiseaseAnatomyAntibodiesAntibody FormationAntifungal AgentsAntigensAttentionAutoimmune DiseasesB-LymphocytesBindingBypassC Type Lectin ReceptorsCandidaCandida albicansCandidiasisCell WallCellsCenters for Disease Control and Prevention (U.S.)DataDetectionDevelopmentDiseaseEpitheliumEventGene MutationGenetic TranscriptionGoalsHealthImmuneImmune responseImmune systemImmunocompromised HostImmunologyIncidenceIndividualInfectionInfectious AgentInflammationInflammatoryInnate Immune ResponseInnate Immune SystemInterferon Type IIInterferonsLifeLigandsLocationLymph Node Subcapsular SinusMacrophageMediatingMedicalModelingModernizationMycosesNF-kappa BOutcomePathway interactionsPatientsPattern recognition receptorPeripheralPersonsPhagocytesPolysaccharidesPredispositionProcessProductionRoleSentinelSepsisSignal TransductionSolubilityStimulusTestingTherapeuticTherapeutic InterventionTimeTissuesVaccinesadaptive immune responseadaptive immunityautoimmune pathogenesiscandidemiadesigndraining lymph nodefungusgenetic signatureglobal healthimprovedinflammatory milieuinnovationinsightmicrobialmigrationnovelnovel therapeutic interventionpathogenphysical propertypreventprotein functionrelB proteinresponsetherapeutically effective
项目摘要
PROJECT SUMMARY
The dialogue between innate and adaptive branches of the immune system is a central paradigm of modern
immunology and is vital for protection against infections as well as for the pathogenesis of autoimmune, allergic
and inflammatory diseases. According to the current model, innate immune sentinels dispersed throughout
peripheral tissues sense, via their pattern recognition receptors (PRRs), the presence of microbial clues or
endogenous moieties released during an infection, are activated and migrate to the draining lymph node (dLN).
This process enables a transfer of “information” from peripheral tissue to the dLN, where the antigen-dependent
adaptive immune response against the pathogen is initiated. The dLN also hosts an initial antigen-independent,
innate immune response governed by migrating phagocytes that enables expansion of the LN and establishes
a pro-inflammatory milieu. These events are required for the development and polarization of the adaptive
immune response. Here, we focused our attention on the capacity of ligands derived from the cell wall of Candida
(C.) albicans to dictate the LN innate response. Our working hypothesis is that the size and solubility of
stimuli that activate the PRRs affect not only the LN innate response itself, but also the final outcome of
the immune response. Also, that the LN innate response initiated by soluble fungal ligands can be
harnessed to develop a potent and protective adaptive immune response to prevent life-threatening
systemic fungal infections. Our preliminary data demonstrate that the physical form of fungal ligands dictates
the location where the initial immune response takes place, and thereby determines the activation of adaptive
immunity. In particular, we have found that small soluble fungal ligands that are immunosilent in the periphery
and do not cause an inflammation in the tissue, become potent immunogens once they reach the dLN. Also, that
the LN innate response initiated by these ligands completely bypasses the need of phagocyte migration from the
periphery into the dLN and, instead, requires a unique gene signature that is characterized by the production of
interferons and that is driven by the activation of the noncanonical NFkB transcription factor RelB in subcapsular
sinus macrophages. Notably, Dectins are required for this process but CARD9, the key signaling adaptor
downstream of Dectins, is largely dispensable. Plus, the initial innate response to the dLN instructs a potent
type 1 adaptive immunity and allows the production of antibodies directed against the most external layer of the
fungal cell wall. Fungal diseases are a global health problem and Candida species are the most common cause
of invasive fungal infections. We propose to unravel how physical properties of the PAMPs can be harnessed as
a therapeutic intervention against systemic fungal infections that are a major medical problem in the US. We
anticipate that identifying new features of the immune response that is anatomically restricted to the LN will help
with the design of an improved vaccine against poorly controlled pathogens.
项目概要
免疫系统的先天性分支和适应性分支之间的对话是现代免疫系统的核心范例
免疫学,对于预防感染以及自身免疫、过敏的发病机制至关重要
根据目前的模型,先天免疫哨兵分散在各处。
外周组织通过其模式识别受体(PRR)感知微生物线索的存在或
感染期间释放的内源部分被激活并迁移至引流淋巴结 (dLN)。
这个过程能够将“信息”从外周组织转移到 dLN,其中抗原依赖性
针对病原体的适应性免疫反应也被启动。
由迁移吞噬细胞控制的先天免疫反应使 LN 扩张并建立
这些事件是适应性的发展和极化所必需的。
在这里,我们将注意力集中在来自念珠菌细胞壁的配体的能力。
(C.) 白色念珠菌决定 LN 的固有反应。我们的工作假设是,白色念珠菌的大小和溶解度。
激活 PRR 的刺激不仅影响 LN 的先天反应本身,而且还影响 LN 的最终结果。
此外,由可溶性真菌配体引发的 LN 固有反应可以是
用于开发有效的保护性适应性免疫反应,以预防危及生命的情况
我们的初步数据表明真菌配体的物理形式决定了
初始免疫反应发生的位置,从而决定适应性的激活
特别是,我们发现了外周免疫沉默的小可溶性真菌配体。
并且不会引起组织炎症,一旦到达 dLN,就会成为有效的免疫原。
由这些配体引发的 LN 固有反应完全绕过了吞噬细胞从 LN 迁移的需要。
外围进入 dLN,相反,需要一个独特的基因签名,其特征是产生
干扰素,由荚膜下非典型 NFkB 转录因子 RelB 的激活驱动
值得注意的是,Dectins 是该过程所必需的,但关键信号适配器 CARD9 是必需的。
Dectins 的下游,在很大程度上是可有可无的,此外,对 dLN 的最初先天反应指示了有效的。
1 型适应性免疫,并允许产生针对最外层的抗体
真菌细胞壁疾病是一个全球性的健康问题,念珠菌属是最常见的原因。
我们建议阐明如何利用 PAMP 的物理特性来研究侵袭性真菌感染。
针对系统性真菌感染的治疗干预,这是美国的一个主要医学问题。
预计识别解剖学上仅限于淋巴结的免疫反应的新特征将有助于
设计针对控制不良的病原体的改进疫苗。
项目成果
期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Host-derived oxidized phospholipids initiate effector-triggered immunity fostering lethality upon microbial encounter.
宿主来源的氧化磷脂启动效应子触发的免疫,在微生物遭遇时产生致命性。
- DOI:
- 发表时间:2023-11-21
- 期刊:
- 影响因子:0
- 作者:Gioia, Marco Di;Poli, Valentina;Tan, Piao J;Spreafico, Roberto;Chu, Anne;Cuenca, Alex G;Gordts, Philip Lsm;Pandolfi, Laura;Meloni, Federica;Witztum, Joseph L;Chou, Janet;Springstead, James R;Zanoni, Ivan
- 通讯作者:Zanoni, Ivan
COVID-19 and emerging viral infections: The case for interferon lambda.
COVID-19 和新出现的病毒感染:干扰素 lambda 的案例。
- DOI:
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Prokunina;Alphonse, Noémie;Dickenson, Ruth E;Durbin, Joan E;Glenn, Jeffrey S;Hartmann, Rune;Kotenko, Sergei V;Lazear, Helen M;O'Brien, Thomas R;Odendall, Charlotte;Onabajo, Olusegun O;Piontkivska, Helen;Santer, Deanna M;Reich
- 通讯作者:Reich
μMAPPS: a novel phasor approach to second harmonic analysis for in vitro-in vivo investigation of collagen microstructure.
μMAPPS:一种新颖的二次谐波分析相量方法,用于胶原微结构的体外体内研究。
- DOI:
- 发表时间:2017-12-12
- 期刊:
- 影响因子:4.6
- 作者:Radaelli, F;D'Alfonso, L;Collini, M;Mingozzi, F;Marongiu, L;Granucci, F;Zanoni, I;Chirico, G;Sironi, L
- 通讯作者:Sironi, L
Microbiome studies in the medical sciences and the need for closer multidisciplinary interplay.
医学中的微生物组研究以及更密切的多学科相互作用的需要。
- DOI:
- 发表时间:2020-02-04
- 期刊:
- 影响因子:7.3
- 作者:Mancini, Nicasio;Peri, Francesco;Rescigno, Maria;Zanoni, Ivan
- 通讯作者:Zanoni, Ivan
Dooming Phagocyte Responses: Inflammatory Effects of Endogenous Oxidized Phospholipids.
毁灭性的吞噬细胞反应:内源性氧化磷脂的炎症作用。
- DOI:
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:Di Gioia, Marco;Zanoni, Ivan
- 通讯作者:Zanoni, Ivan
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ivan Zanoni其他文献
Ivan Zanoni的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ivan Zanoni', 18)}}的其他基金
Macrophage immunometabolism controls septic shock
巨噬细胞免疫代谢控制感染性休克
- 批准号:
10658162 - 财政年份:2023
- 资助金额:
$ 51.38万 - 项目类别:
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans
通过调节真菌甘露聚糖的物理特性开发新型佐剂策略
- 批准号:
10490881 - 财政年份:2021
- 资助金额:
$ 51.38万 - 项目类别:
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans
通过调节真菌甘露聚糖的物理特性开发新型佐剂策略
- 批准号:
10687182 - 财政年份:2021
- 资助金额:
$ 51.38万 - 项目类别:
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans
通过调节真菌甘露聚糖的物理特性开发新型佐剂策略
- 批准号:
10338399 - 财政年份:2021
- 资助金额:
$ 51.38万 - 项目类别:
Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
- 批准号:
9232989 - 财政年份:2016
- 资助金额:
$ 51.38万 - 项目类别:
Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
- 批准号:
9122779 - 财政年份:2016
- 资助金额:
$ 51.38万 - 项目类别:
Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
- 批准号:
10434924 - 财政年份:2016
- 资助金额:
$ 51.38万 - 项目类别:
Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
- 批准号:
10293993 - 财政年份:2016
- 资助金额:
$ 51.38万 - 项目类别:
相似国自然基金
Long-TSLP和Short-TSLP佐剂对新冠重组蛋白疫苗免疫应答的影响与作用机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:面上项目
新疆一枝蒿多糖佐剂影响DCs调控Th1/Th2免疫应答的重要机制
- 批准号:31960164
- 批准年份:2019
- 资助金额:40 万元
- 项目类别:地区科学基金项目
草甘膦除草剂中佐剂对大豆根际土壤微生物群落的影响及其机制研究
- 批准号:31870495
- 批准年份:2018
- 资助金额:60.0 万元
- 项目类别:面上项目
亚细胞环境响应性的纳米材料与TLR激动剂复合制剂对疫苗免疫原性的影响
- 批准号:31600812
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
壮医药线点灸对佐剂关节炎大鼠NF-κB/IκB信号通路的影响
- 批准号:81360571
- 批准年份:2013
- 资助金额:48.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Multisensory augmentation to improve the standing balance of people with chronic stroke
多感觉增强改善慢性中风患者的站立平衡
- 批准号:
10640299 - 财政年份:2023
- 资助金额:
$ 51.38万 - 项目类别:
Enhancing cognitive function in breast cancer survivors through community-based aerobic exercise training
通过社区有氧运动训练增强乳腺癌幸存者的认知功能
- 批准号:
10691808 - 财政年份:2023
- 资助金额:
$ 51.38万 - 项目类别:
Developing RNA Vaccines to Treat Peanut Hypersensitivity
开发治疗花生过敏的 RNA 疫苗
- 批准号:
10570339 - 财政年份:2023
- 资助金额:
$ 51.38万 - 项目类别:
Cellular perturbations to enhance precise therapeutic genome editing to treat FTD/ALS
细胞扰动增强精确治疗基因组编辑以治疗 FTD/ALS
- 批准号:
10607752 - 财政年份:2023
- 资助金额:
$ 51.38万 - 项目类别:
Project 3: Credentialing CDK 4/6 inhibitors used with radiation as an effective treatment strategy in locally advanced ER+ and TNBC
项目 3:认证 CDK 4/6 抑制剂与放射结合使用作为局部晚期 ER 和 TNBC 的有效治疗策略
- 批准号:
10554474 - 财政年份:2023
- 资助金额:
$ 51.38万 - 项目类别: